Alpha Genesis

What Alpha Genesis does

Alpha Genesis, Inc. (AGI) is a U.S.-based nonhuman primate research services provider headquartered in Yemassee, South Carolina, operating purpose-bred rhesus and cynomolgus macaque colonies and integrated preclinical research infrastructure since 2003. The company's core offerings span the full NHP research lifecycle: supply of purpose-bred nonhuman primates with veterinary oversight and health documentation; CDC-compliant quarantine, import support, secure housing, and long-term colony management; GLP-capable and non-GLP contract research services covering pharmacology, pharmacokinetics, toxicology, surgical and interventional models, ophthalmology, orthopedics, imaging, and translational studies; and custom biological sample collections (whole blood, serum, plasma, PBMCs, tissues). A more recent add-on is research animal retirement services integrated into colony management. The company also manages Morgan Island off the coast of Beaufort, South Carolina, home to 3,500-4,000 rhesus macaques, under a $4.1 million annual federal contract with the CDC.

The underlying technology is physical and regulatory rather than digital: USDA-registered, OLAW-assured, AAALAC-accredited, and GLP-compliant facilities with animal breeding infrastructure, quarantine operations, colony management systems, and preclinical study execution capabilities. Proprietary positioning rests on integrated domestic execution that reduces vendor fragmentation between animal supplier, quarantine provider, housing site, and research vendor, plus regulatory credibility supported by a successful USDA Triennial Re-Licensing Inspection (2025).

Alpha Genesis generates revenue through four streams: contract research services (professional services model), NHP animal sales and breeding (one-time/license model), CDC and federal government contracts (recurring, anchored by the Morgan Island management contract), and CDC quarantine services (managed services). Go-to-market is direct enterprise field sales targeting biotech and pharmaceutical sponsors, government research programs, and academic investigators, with custom quote-based pricing and multi-year contracts. The company has scaled via sustained federal funding inflows (approximately $32.65 million in 14 funding rounds between 2017 and 2022, including NIH as a named investor), a recent 40% expansion of breeding operations (2025-11), and a $3 million+ GLP capacity investment (2025-10), all framed around U.S. scientific self-reliance and reducing dependence on imported research animals.

Name

Alpha Genesis

Legal name

Alpha Genesis, Inc.

Website

https://alphagenesisinc.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Alpha Genesis is a U.S. nonhuman primate research services provider offering purpose-bred macaques, CDC-compliant quarantine, GLP-capable preclinical contract research, and biological sample collections to biotech and pharmaceutical sponsors, federal agencies, and academic investigators.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Veterinary Services (54194), Support Activities for Animal Production (11521)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

akta.pro secondary industry

Diagnostics & Laboratory Coordination (Sample Collection, Lab Liaison, Interpretation) (AFACALAE)

Keywords

• Preclinical contract research
• Nonhuman primate models
• GLP toxicology services
• CDC quarantine services
• Biomedical research services

Headquarters

HQ city

Yemassee

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services: Alpha Genesis generates revenue through GLP-capable and non-GLP preclinical contract research services including pharmacology, PK, toxicology, surgical, interventional, ophthalmology, orthopedic, and translational studies. Clients sponsor studies with the company coordinating animals, procedures, samples, documentation, and sponsor communication.
2. NHP Animal Sales and Breeding: The company breeds and sells purpose-bred nonhuman primates (rhesus and cynomolgus macaques) for research purposes. Revenue is generated through animal availability planning and sales to sponsors.
3. Federal Government Contracts: Alpha Genesis manages Morgan Island under a $4.1 million annual federal contract for primate breeding operations.
4. CDC Quarantine Services: The company provides CDC-compliant quarantine, import support, and housing services for nonhuman primates, generating recurring revenue from government and commercial sponsors requiring quarantine capacity.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Alpha Genesis supplies purpose-bred rhesus and cynomolgus macaques for biomedical research and operates CDC-compliant domestic quarantine, housing, and import support for nonhuman primates. The company also delivers GLP-capable and non-GLP preclinical contract research across pharmacology, PK, toxicology, surgical, interventional, ophthalmology, orthopedic, and translational studies, including custom biological sample collection (whole blood, serum, plasma, PBMCs, tissues). It integrates animal resources, quarantine, procedures, samples, and documentation under a single sponsor-facing platform and additionally offers research animal retirement services.

Product overview

Alpha Genesis is a U.S.-based nonhuman primate research services provider offering a coordinated platform for complex preclinical programs. The core offerings include Nonhuman Primate Models (purpose-bred rhesus and cynomolgus macaques), CDC Quarantine & Housing services, Contract Research Services (GLP-capable preclinical studies), and Biological Samples (custom collections). These services are integrated to support the full research lifecycle from animal sourcing and quarantine through study execution and sample delivery. Additionally, the company offers Research Animal Retirement Services for lifetime care of research animals. The company manages Morgan Island, South Carolina, under a $4.1 million annual federal contract, and provides services to biotechnology companies, pharmaceutical companies, government research programs, and academic investigators.

Differentiator

Problem solved

Functional benefit

Products and services

• Nonhuman Primate Models Supply of purpose-bred rhesus and cynomolgus macaques supported by veterinary oversight, health documentation, intake review, social housing practices, and experienced animal care teams; sold to biotech, pharma, government, and academic sponsors needing animals matched to study requirements and timelines.
• CDC Quarantine and Housing CDC-compliant domestic quarantine, import support, secure housing, sponsor-owned animal support, and long-term colony management for programs requiring U.S. quarantine capacity, experienced animal handling, and operational continuity.
• Contract Research Services GLP-capable and non-GLP preclinical study support covering pharmacology, pharmacokinetics, toxicology, surgical, interventional, ophthalmology, orthopedic, imaging, and translational research, with teams coordinating animals, procedures, samples, documentation, and sponsor communication.
• Biological Samples Custom biological material collection from NHP models, including whole blood, serum, plasma, PBMCs, tissues, and other study-specific matrices, with scheduled collections, matrix-specific handling, processing, and documentation for downstream analysis.
• Research Animal Retirement Services Lifetime care and retirement services for research animals, with retirement planning integrated into broader colony management, study planning, and sponsor discussions.

Quantifiable outcome

• 40% expansion of primate breeding operations in South Carolina to enhance U.S. scientific self-reliance
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Charles River Laboratories: Global preclinical CRO with significant NHP research models and contract research services business. Directly comparable to AGI's GLP-capable toxicology/PK and NHP supply offerings but operates at much larger scale across multiple species and geographies.
• Labcorp Drug Development (formerly Covance): Large CRO with extensive preclinical and clinical research services including NHP toxicology and PK studies. Overlaps with AGI's GLP-capable contract research services but serves a broader sponsor base and service portfolio.
• IQVIA: Global CRO and life sciences services provider with preclinical capabilities. Less NHP-specialized than AGI but addresses the same biotech and pharma sponsor demand for outsourced preclinical and translational research support.

Direct peers

• Inotiv: Preclinical CRO and research models provider (incorporating Envigo and Bio-Techne assets) with a strong nonhuman primate breeding and contract research footprint. Closest direct competitor to AGI's integrated NHP models and GLP study services for pharma/biotech sponsors.
• Marshall BioResources: Specialty breeder of purpose-bred research animals including NHPs, supplying pharmaceutical and academic research programs. Comparable to AGI's purpose-bred rhesus/cynomolgus macaque sales and breeding operations.
• Taconic Biosciences: Provider of genetically engineered and purpose-bred research animal models with health monitoring and colony management services. Comparable to AGI's purpose-bred animal and colony management offering, though Taconic's rodent focus differs from AGI's primate specialty.
• The Jackson Laboratory: Nonprofit provider of mouse models and preclinical research services with significant animal production and phenotyping capabilities. Comparable to AGI in providing purpose-bred models and contract research services to pharma, biotech, and academic customers.

Emerging players

• WuXi AppTec: China-headquartered preclinical CRO with substantial nonhuman primate breeding and toxicology capacity. Competes with AGI for global NHP-based preclinical studies, particularly relevant given U.S.-China NHP supply dynamics driving AGI's domestic expansion thesis.
• JOINN Laboratories: China-based preclinical CRO with significant nonhuman primate research capabilities serving global biopharma. Comparable to AGI's GLP preclinical and toxicology services but operating primarily from Asian facilities with different regulatory positioning.
• Maccine Pte Ltd: Singapore-based preclinical CRO specializing in NHP pharmacology, toxicology, and disease models for biotech and pharma sponsors. Directly comparable to AGI's NHP-focused contract research services, with a regional rather than U.S.-centric footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/alphagenesisinc
• Facebookfacebook.com/AlphaGenesis
• LinkedInlinkedin.com/company/alpha-genesis-inc.

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds14 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alpha Genesis